Can vitamin D protect against age-related macular degeneration or slow its progression?

Kai Kaarniranta¹, Elżbieta Pawlowska², Joanna Szczepanska³, Aleksandra Jabłkowska⁴ and Janusz Blasiak⁵

¹Department of Ophthalmology, University of Eastern Finland, Kuopio 70211, Finland and Department of Ophthalmology, Kuopio University Hospital, Kuopio 70029, Finland; ²Department of Orthodontics, Medical University of Łódź, 92-216 Łódź, Poland; ³Department of Pediatric Dentistry, Medical University of Łódź, 92-216 Łódź, Poland; ⁴Department of Infectious and Liver Diseases, W. Bieganski Hospital, 91-347 Łódź, Poland; ⁵Department of Molecular Genetics, Faculty of Biology and Environmental Protection, University of Łódź, 90-236 Łódź, Poland

Dietary vitamin D plays an important role in maintaining proper vision. Age-related macular degeneration (AMD) is a complex eye disease with unknown pathogenesis. Studies on dietary supplementation and AMD occurrence and progression have produced conflicting results. In its advanced stage, AMD may be associated with apoptosis, pyroptosis or necroptosis of retinal cells. Vitamin D has been reported to play a role in modulating each of these programmed death pathways. Vitamin D is a modulator of the immune system and it acts synergistically with two members of the regulators of complement activation family H and I, whose specific variants are the most important genetic factors for AMD pathogenesis. Angiogenesis is an essential component of the neovascular form of AMD, the most devastating type of the disease and vitamin D is reputed to possess antiangiogenic properties. Cellular DNA damage response is weakened in AMD patients and so it is another process that can be modulated by vitamin D. Finally, impaired autophagy is claimed to play a role in AMD and emerging evidence suggests that vitamin D can influence autophagy. Therefore, several pathways of vitamin D metabolism and AMD pathogenesis overlap, suggesting that vitamin D could modulate the course of AMD.

Key words: dietary vitamin D, age-related macular degeneration, autophagy, inflammation, immune response

Received: 30 April, 2019; revised: 31 May, 2019; accepted: 03 June, 2019; available on-line: 18 June, 2019

INTRODUCTION

Age-related macular degeneration

Age-related macular degeneration (AMD) is a complex eye disease destroying the macula, the part of the retina responsible for sharp central vision and it is the leading cause of vision loss in the elderly in many countries (Reibaldi et al., 2016). Although pathogenesis of AMD is largely unknown, an inappropriate diet can influence its occurrence and progression (Aoki et al., 2016; Broadhead et al., 2015; Everett et al., 2006; Parekh et al., 2007; Seddon et al., 2011; Stevens et al., 2015). More detail on the role of diet in AMD pathogenesis is provided in a subsequent section.

AMD is an emerging medical problem as the number of people affected by AMD and the cost of medical care increase (Wong et al., 2004). In its advanced stage, the disease occurs in two basic forms: dry (non-neovascular) and wet (neovascular). Whereas there have been some successes in the treatment of wet AMD with inhibitors of vascular endothelial growth factor A (VEGFA), important for neovascularization, there is no remedy for the dry form of the disease (Maguire & Campbell, 2010).

Genetic, environmental and life-style factors have been implicated in AMD pathogenesis (Fig. 1). AMD mainly affects individuals over 65 years old. Mutations in the genes coding for complement factors H and I as well as some other genes, including those participating in lipid metabolism, other components of the immune system, and parts of the vascular system, represent the main genetic risk factors for AMD (Lyzogubov et al., 2016). Studies conducted in the United States indicate that white race and female sex seem to be strongly associated with the occurrence of AMD – in 2010, 2.5% of the white adults aged 50 or older had AMD, while the disease occurrence in blacks, Hispanics and people of other races was less than 1%; furthermore, the majority i.e. 65% of AMD cases occurred in women (https://nei.nih.gov/eyedata/amd). Changes in the cellular epi-genetic pattern (epimutations) can also be important in the pathogenesis of AMD (Blasiak et al., 2013b). Oxidative stress, protein aggregation and inflammation along with genetic risk factors, are all claimed to be involved in AMD pathogenesis (Kauppinen et al., 2016). Drusen, small yellowish objects containing damaged material, are a characteristic feature of the disease and their presence is a clinical hallmark of AMD.
Progression of AMD leads to a massive macular degeneration accompanied by dysfunctional retinal pigment epithelium (RPE) cells and photoreceptors, which may die in the end stage of the disease. The death of the retinal cells in AMD is likely executed by apoptotic, pyroptotic or necroptotic program, but it is not known whether any one of these mechanisms predominates in the AMD pathology (Kaarniranta et al., 2017).

Vitamin D is claimed to possess a protective potential in many human diseases, including various cancers, cardiovascular disease, diseases of bones, kidney and muscles, hypertension, type 2 diabetes mellitus and others (Ahn et al., 2016; Al Mheid & Quyyumi, 2017; Duque et al., 2017; Ekmekcioglu et al., 2017; Field et al., 2013; Gaksch et al., 2017; Grubler et al., 2017; Heaney, 2008; Hill & Aspray, 2017). It seems to have attracted attention in disease prevention due to its key role as a nutritional factor (Sharma et al., 2017).

1,25-Dihydroxyvitamin D [calcitriol, 1,25(OH)2D] is the active form of vitamin D, which binds to its receptor (the vitamin D receptor, VDR) to activate expression of specific genes (Haussler et al., 2013). In humans, inactive vitamin D is converted into 25-hydroxyvitamin D [calcidiol, calcifediol, 25(OH)D] in the liver by CYP2R1 (cytochrome P450 family 2 subfamily R member 1) and then hydroxylated to 1,25(OH)2D in the kidney by 1-α-hydroxylase (CYP27B1). This final step of pro-vitamin D activation is upregulated by the parathyroid hormone (PTH).

Synthesis of vitamin D in the skin requires UV radiation, which can induce DNA damage, preferentially cyclobutane pyrimidine dimers and (6-4)-pyrimidine-pyrimidine photoproducts, which are found in many skin cancers, including melanoma (reviewed in (Pawlowska et al., 2016). Vitamin D protects the skin against UV-induced aging and damage in many pathways that may save it from UV-induced DNA damage and the resulting skin cancer (reviewed in: Piotrowska et al., 2016).

Major functions of the products of genes targeted by 1,25(OH)2D are the absorption of dietary calcium and phosphorus and bone mineralization. Therefore, 1,25(OH)2D is intimately involved in the calcium metabolism. Osteoporosis is likely the most distinctive example of a vitamin D age-related pathology (Gallagher, 2013; Hill & Aspray, 2017; Hill et al., 2013). This inspired us to evaluate the potential of 1,25(OH)2D to slow down or stop the process of aging, or even to reverse it. This issue is closely linked with the role of vitamin D in the pathogenesis and treatment of age-related diseases. The vitamin D receptor is expressed in human retinal pigment epithelium cells as evidenced for ARPE-19 cells (Alsalem et al., 2014). It will be demonstrated that AMD and vitamin D share some common features, e.g. both are associated with aging and the immune system.

**VITAMIN D AND AGE-RELATED MACULAR DEGENERATION**

**Epidemiology**

No specific association was found between vitamin D deficiency and AMD in a population of elderly subjects living in Bordeaux, France (Cougnard-Gregoire et al., 2015). Similar results were obtained in a population of Israeli individuals aged over 60 years (Golan et al., 2011). No causal association between vitamin D and early and neovascular AMD were observed in a population-based, cross-sectional study enrolling individuals from 7 European countries (McKay et al., 2017). That study also detected no association between 1,25(OH)2D serum levels and polymorphisms in the genes involved in vitamin
D metabolism, including glucocorticoid genes, VDR, CYP2R1 and CYP27B1, and the occurrence of those three forms in AMD. There was no association between vitamin D status and early AMD in the recently published results of the Atherosclerosis Risk in Communities (ARIC), a cross-sectional study enrolling nearly 8,000 Caucasians and 2,000 African Americans (Millen et al., 2017).

One large-scale meta-analysis observed a positive correlation between new AMD cases and vitamin D deficiency (Day et al., 2012). As the authors emphasized, this was the first study analyzing the incidence, not the prevalence, of AMD in a vitamin D association study. There is one interesting investigation which examined the association between AMD and vitamin D, i.e. a lower dietary intake of the vitamin was observed in twins with severe AMD than in monozygotic co-twins with less severe AMD (Seddon et al., 2011). That study had an excellent experimental design and revealed an important finding, i.e. vitamin D deficiency might be more strictly associated with the later phases of the disease, when it is especially devastating, rather than with its occurrence. However, vitamin D was not the only factor behind the clinical discordance, since smoking, betaine and methionine intake also contributed to the observed differences. The next important piece of information emerging from that trial is that not only the genetic characteristics, but also the epigenetic profile seems to be important in the development of AMD. However, there were too few subjects enrolled in the trial to permit the elucidation of epigenetic mechanisms in AMD pathogenesis (Blasinska et al., 2013b; Hjelmeland, 2011; Hutchinson et al., 2014; Katoh, 2013; Kwa & Thrimawithana, 2014; Liu et al., 2012). Somewhat in line with that study are results pointing to a lower mean level of 25(OH)D in neovascular AMD than in its non-neovascular counterpart (Itty et al., 2014).

Only a few studies have addressed the anatomical relationships between the changes occurring in the retina in AMD and their association with vitamin D status. It was noted that vitamin D deficiency in older subjects with no clinical signs of AMD was associated with a reduced macular thickness (Graffe et al., 2012). The results of that study may be important from the perspective of AMD diagnosis in its early, preclinical stage. A lower serum concentration of 25(OH)D was observed in wet AMD patients with subretinal fibrosis, suggesting that the vitamin D status could be related to the phenotypical diversity of AMD (Singh, 2014). A trial conducted on a group of older French individuals revealed that a vitamin D deficiency in AMD patients, measured as the 25(OH)D serum concentration, was associated with a decreased thickness of the ganglion cell complex (GCC).

It has been postulated that the effect of vitamin D in the eye might depend on which region is affected by a particular disease (Uro et al., 2015). Furthermore, it has been proposed that the association between serum levels of 25(OH)D might depend on sex, which in turn could be due to differences in the sunlight exposure resulting from different behaviors (Kim et al., 2014). It has been speculated that the 25(OH)D levels could act preventively in late AMD and a similar effect was suspected in diabetic retinopathy, although it seems less likely in case of the dry eye syndrome and cataract.

In a meta-analysis, serum 25(OH)D concentrations below 50 nmol/L were claimed to be associated with late AMD, and conversely, high concentrations were considered to confer protection against AMD (Annweiler et al., 2016). However, there is no consensus about which concentration of vitamin D in the serum can be considered as “normal” and “lower/higher”. Moreover, as mentioned, it is not only 25(OH)D in the serum which is important, the intracellular 1,25(OH)2D concentrations should also be taken into account when examining the relationship between vitamin D and the disease.

It has been suggested that high serum concentrations of 25(OH)D can confer protection against early AMD in individuals aged less than 75 years in a population of postmenopausal women (the Carotenoids in Age-Related Eye Disease Study, CAREDS) (Millen et al., 2011). Interestingly, it was documented that vitamin D exerted a protective effect to UV irradiation against neovascular AMD in 481 sibling pairs (Morrison et al., 2011). The serum 25(OH)D concentrations were slightly higher in unaffected individuals than in their AMD-affected counterparts, although that difference was not statistically significant. An evaluation of the metabolome of neovascular AMD patients revealed several unique features as compared to their age-matched controls, including alterations in vitamin D-related metabolites (Osborn et al., 2013).

In summary, some large population-based studies have reported a beneficial effect of vitamin D in AMD prevention, but others have not detected any benefits. It seems that many factors, including ethnicity, dietary habits, genotypes with elevated susceptibility for AMD, and coexisting diseases could be confounding factors.

**Diet**

There is no consensus about whether there should be dietary recommendations as a way to prevent AMD or to slow down its progression. In general, it seems that early AMD can be accelerated by the intake of fat-rich foods (mono-, trans- or polyunsaturated fatty acids) (Seddon et al., 2003; Seddon et al., 2011) and reduced by a low intake of saturated fat, fish and nuts (Cugati et al., 2007; Wang et al., 2007). The initial large-scale study on how dietary risk factors could influence AMD was conducted in the first National Health and Nutrition Examination Survey (NHANES), which suggested that a diet rich in fruits and vegetables, and its supplementation with vitamins, could reduce the risk of AMD (Goldberg et al., 1988). The conclusion emerging from the third NHANES was that vitamin D might protect against AMD (Parekh et al., 2007). A small-scale population study on AMD in Japan showed that low intakes of n-3 fatty acids, α-tocopherol, zinc, vitamin D, vitamin C, and β-carotene were associated with an increased risk of developing the neovascular form of the disease (Aoki et al., 2016).

Nutritional risk factors for AMD have been assessed in two large-scale trials: AREDS (Age-Related Eye Disease Study) and AREDS2 (Chew, 2017). AREDS revealed that antioxidant vitamins (C, E and β-carotene), zinc and the combination of these vitamins with zinc (AREDS formulation, AREDS supplements) substantially reduced the risk of AMD progression to the late stage in a median 6.5 years follow-up study extended to 10 years (Chew et al., 2014). In addition, AREDS proposed some dietary recommendations to slow down the progression of AMD and these have been confirmed in later studies, including those mentioned above. In AREDS2, β-carotene was replaced with lutein and zeaxanthin, as β-carotene was suspected to cause lung cancer in former smokers (Chew et al., 2012). In general, despite certain controversial aspects, the subsequent AREDS2 confirmed a positive effect of some of the dietary compounds reported in the previous...
study and extended it to some diseases coexisting with AMD, including CVD and impaired cognitive functions (Chew et al., 2012; Chew et al., 2014). It is beyond the scope of this review to discuss all of the interesting aspects emerging from the AREDS/AREDS2 studies, especially since they are still providing some new data and evidence.

Large-scale cohort studies associating AMD with the diet are important if we are to understand better the mechanisms of AMD pathogenesis, and in that way to provide the general population with some reliable and relevant nutritional recommendations. Nonetheless, it should be recognized that they are complicated by many confounding factors, which should be carefully controlled in the study design. For example, the tragedy of β-carotene supplementation and lung cancer shows that not all important aspects of trial design can be anticipated beforehand.

VITAMIN D’S POTENTIAL TO MODULATE AMD RISK FACTORS AND ASSOCIATED STATES

Aging

The final step of vitamin D activation occurs in the kidney (Fig. 2) and this is expected to decrease with age as there is a decline in the general renal function with age (de Jongh et al., 2017; Geraci et al., 2017). It was demonstrated that stimulation with PTH resulted in a substantially reduced production of 1,25(OH)2D in elderly people, in comparison to younger individuals (Kin-yamu et al., 1996).

In general, calcium absorption represents the sum of its active transport and passive diffusion (Christakos et al., 2011; Ebeling et al., 1992; Gonzalez Pardo & Russo de Boland, 2013; Sarma & Yang, 2011). Calcium absorption declines with age and this decrease can be associated with a disturbed activity of the calcium transport proteins regulated by 1,25(OH)2D (Christakos et al., 2011; Gonzalez Pardo & Russo de Boland, 2013). Intestinal concentration of VDR can be critical for calcium absorption and a decrease in the numbers of VDRs with age has been observed in humans and experimental animals (de Jongh et al., 2017; Ebeling et al., 1992; Horst et al., 1990; Kinyamu et al., 1996).

1,25-dihydroxyvitamin D also controls an endocrine axis containing the bone-derived hormone FGF23 and the kidney-expressed klotho after association with VDR (Haussler et al., 2012). Such interaction with the involvement of the CYP24A1 and CYP27B1 enzymes, prevents hyperphosphatemia and ectopic calcification, and allows 1,25(OH)2D to maintain mineral integrity of the bones and maintain optimal functions of the kidneys, modulating the aging processes and promoting health span.

The precursor of vitamin D (cholecalciferol) is mainly produced in the skin and requires exposure to UV light. On the other hand, chronic exposure to sunlight can result in premature skin aging – skin photoaging (Kanaki et al., 2016). It has been demonstrated that the production of pro-vitamin D in skin explants decreases with age (MacLaughlin & Holick, 1985). In subsequent studies, it was observed that the vitamin D endocrine system regulated skin aging and furthermore, not only a deficit, but also an overproduction of vitamin D could result in premature skin aging (Reichrath, 2012). There are some controversies surrounding the link between skin aging and vitamin D – there appears to be no correlation be-

between the serum 25(OH)D concentration and facial skin aging (Dawoud et al., 2016).

Another problem associated with vitamin D metabolism in aging is its deficiency due to either insufficient dietary supply and/or lack of enough exposure to sunlight, both of which are common in the elderly (Neele et al., 2008).

In summary, the conversion of vitamin D into its active forms and its role in the cell and organism homeostasis strongly depends on aging (Fig. 2). The disturbance in vitamin D homeostasis in the aging organism raises questions about its role in the pathogenesis of age-related diseases.

Susceptibility genes

Mutations in the genes of the complement system are the most significant genetic factors in the pathogenesis of AMD. It has been demonstrated that two risk alleles for the CFH and CFI genotypes can act synergistically with the vitamin D status, as measured by the serum 25(OH)D levels (Millen et al., 2015; Millen et al., 2011). However, the authors emphasized that they had a relatively small sample size and concluded that the results could be due to chance or residual confounding.
AMD genetic risk factors include variations in the sequence (mutations) and expression of the HTRA1 (high temperature requirement protein A1) gene located in the 10q26 chromosomal region, which has many single nucleotide polymorphisms (SNPs), creating haplotypes with high susceptibility to AMD (Liao et al., 2017). A reduced expression of HTRA1 has been associated with drusen formation (Pahl et al., 2013). That study was performed on the 10q26-orthologue region of rhesus monkeys; it revealed that the promoter of the HTRA1 gene contained 9 binding sites for the vitamin D-dependent transcription factor VDR. One of these sites was inactivated by an allele of an SNP present in the HTRA1 promoter, which was associated with drusen formation. An in vitro assay revealed that the drusen risk allele decreased the activity of the HTRA1 promoter after stimulation with 1,25(OH)2D, which was apparently at odds with previously published results. Therefore, not only an increase in the expression of the HTRA1 gene, but also an imbalance in its expression can be associated with an increased risk for developing the AMD drusen phenotype.

The evidence for an association between variations in the AMD susceptibility genes and vitamin D status would be more convincing if a concomitant functional study of the variant of the investigated gene had been performed, as in the studies described above. Moreover, it should be taken into account that expression of a single gene results from interaction of many other gene products.

Inflammation

NLRP3 [NLR (neural retina leucine zipper) family pyrin domain containing 3, NALP3, cryopyrin] is a component of the inflammasome and an important element of the innate immune system. It activates caspase-1 and this leads to subsequent release of interleukin-1α (IL-1α) and IL-1β (He et al., 2016). It is activated by different stimuli, including various pathogens and products of stressed, damaged or dying cells. NLRP3 activation has been associated with pathogenesis of AMD and its role has been linked with autophagy (Celkova et al., 2015; Kauppinen et al., 2016). It was reported that both, 1,25(OH)2D and 25(OH)D had increased the release of IL-1α from human monocytes with this effect being dependent on caspase-1 and NLRP3 (Tulk et al., 2015).

Vitamin D can exert differential effects on the production of pro- and anti-inflammatory cytokines, for example, this vitamin inhibited the release of tumor necrosis factor-α (TNF-α), interleukin-2 (IL-2) and IL-12, as well as interferon-γ (IFN-γ), while it exerted a stimulatory effect on the release of anti-inflammatory cytokines, including IL-4, IL-10 and transforming growth factor-β (TGF-β) (Penna & Adorini, 2000). These and other studies suggest that vitamin D can be considered as an anti-inflammatory agent. Treatment with 1,25(OH)2D has been shown to reduce the corneal inflammatory response to bacterial infection (Kernacki & Berk, 1994).

It was shown that 6 weeks’ administration of vitamin D in 12-month aged mice significantly improved indicators of retinal inflammation and aging (Lee et al., 2012). A reduction in amyloid beta accumulation and a decline in the population of retinal macrophages were observed, and these changes correlated with improvements in the animals’ visual functions. Therefore, that study provided more evidence of the D potential to protect against the changes associated with AMD and AD.

Emerging evidence suggests that vitamin D is an important regulator of the immune system (see (Wu et al., 2018) for review). However, the exact mechanism of that regulation is not completely known. Vitamin D-metabolizing enzymes and VDR are present in various immunological cells including macrophages, B and T cells, antigen-presenting cells and others (Prietl et al., 2013). Vitamin D was reported to stimulate differentiation of immune cells, decrease expression of proinflammatory Th1 (IL2, interferon γ, TNFα), but increase antinflammatory Th2 (IL3-5, 10) cytokines (Prietl et al., 2013). It also supports the production of antimicrobial peptides with a decrease in antibody production (Reichrath et al., 2016).

Angiogenesis

Angiogenesis plays a crucial role in the pathogenesis of neovascular AMD; angiogenesis is the formation of new vessels which determines the disease phenotype. This process can be considered as inflammatory angiogenesis, which in contrast to its cancer counterpart, is not a single-cell derived event. However, some results point to the presence of a cross-talk between inflammatory responses at the cellular and molecular levels.

Several studies have highlighted the antiangiogenic potential of vitamin D. Suzuki and coworkers (Suzuki et al., 2000) reported that topical administration of 1,25(OH)2D in mice inhibited corneal neovascularization. These results were confirmed in an in vitro experiment using human corneal epithelial cells, suggesting that this vitamin can inhibit production of various cytokines, including IL-1, granulocyte-macrophage colony-stimulating factor, and TNF-α, which can stimulate migration of the Langerhans cells (Suzuki et al., 2000).

Treatment with vitamin D has been also shown to reduce retinal neovascularization in mice with oxygen-induced retinopathy (Albert et al., 2007). These studies revealed that 1,25(OH)2D inhibited morphogenesis in capillary endothelial cells without affecting their migration or proliferation. However, there is one previous report that vitamin D could inhibit migration of endothelial cells (Hisa et al., 1996). Although mechanisms underpinning the neovascularization encountered in cancer and retinopathies need not be identical, there may be some common pathways e.g. it has been suggested that 1,25(OH)2D could inhibit expression of Bel-2 in retinoblastoma and endothelial cells (Nebbioso et al., 2017; Shokravi et al., 1995).

Retinal cell death

Cell death in the retina occurs in the final stages of several eye disorders, including AMD. However, it is not completely clear how these cells die in AMD (Kaarniranta et al., 2017). In general, retinal cells in AMD can undergo apoptosis or necrosis and furthermore apoptosis can be executed in either a caspase-dependent or an independent pathway (Ferrington et al., 2006). It seems that since several different kinds of cells are present in AMD, i.e. RPE cells, choriocapillaries and neurons, various modes of cell death can occur at any given time, and although it has been extensively investigated, the problem of cell death in AMD is still unresolved.

The basic debate centers on the kind of cell death in AMD, i.e. is it a programmed death or necrosis? As stated above, pure necrosis is rather unlikely as the mechanism of cell death, and instead its programmed version, necroptosis, seems more plausible (Blasik et al., 2017). Similarly, not only apoptosis, but also a version of apoptosis dependent on caspase-1, designated as pyroptosis, may be involved, especially since this pathway is related
to inflammation (Bergbaken et al., 2009; Brandstetter et al., 2016). We have proposed that autophagy could be decisive in the choice of cell death mode in AMD (Kaarniranta et al., 2017). In order to assess the protective potential of vitamin D in AMD, its influence on apoptosis, pyroptosis and necroptosis should be explored.

In view of vitamin D’s immunoregulatory and anti-inflammatory properties, in general it can be considered as a pro-survival molecule (Chirumbolo et al., 2017). This is due to its role in the stress response mediated through calcium oscillatory signaling to induce autophagy or apoptosis via its modulatory activity to combat calcium overload (Chirumbolo et al., 2017; Wilson et al., 2011). Therefore, because it possesses immunoregulatory properties, vitamin D could induce autophagy instead of a programmed death in AMD-associated stress conditions, and in this way postpone the induction, or slow down progression of AMD. Vitamin D has been reported to protect human islet cells from apoptosis induced by cytokines through upregulation of A20, which is a zinc finger anti-apoptotic protein (Riachy et al., 2002).

It was shown that administration of a cholecalciferol cholesterol emulsion, a precursor of 1,25(OH)2D, suppressed pyroptosis signaling in an animal experimental model of colitis where infected macrophages were reported to trigger apoptosis (Xiong et al., 2016). If the activity of caspase-8 was inhibited, apoptosis was switched to necroptosis through vitamin D regulation with interconnections to TNF-α and type I IFN (Xu et al., 2014). Therefore, vitamin D can be considered as a compound capable of modulating programmed cell death, justifying its use in research in AMD prevention and therapy.

DNA damage response

Oxidative stress is considered as a primary risk factor for AMD, as well as being involved in conditions encountered in RPE cells associated with AMD as a consequence of exposure to other primary risk factors, e.g. tobacco smoking, consumption of a diet rich in polyunsaturated fatty acids, etc. (Blasiak et al., 2014). This kind of stress is associated with an overproduction of reactive oxygen species (ROS) which are capable of damaging cellular macromolecules, including DNA (Jarrett & Boulton, 2012). Damage to both mitochondrial and nuclear DNA has been considered to play a role in pathogenesis of AMD (Blasiak & Szaflik, 2011; Blasiak et al., 2013a; Ferrington et al., 2016). We and others have demonstrated that AMD patients displayed more evidence of DNA damage and impaired DNA repair, as compared to control individuals without vision disturbances (Hyttinen et al., 2017; Szaflik et al., 2009). There may be changes in the DNA repair capabilities in AMD patients due to mutations in DNA repair genes (Blasiak et al., 2012; Synowiec et al., 2012). However, it is not known whether the increased levels of DNA damage in AMD patients are the reasons or consequences of the disease since both are possible.

DNA damage induces a cascade of events leading to its repair, tolerance or cell death; this is collectively known as the DNA damage response (DDR) (Zhou & Elledge, 2000). Consequently, a difference in the extent of DNA damage between two cells can result not only from a difference in DNA-damaging factors, but also from the cellular reaction to either factor. An increased level of DNA damage in the cell can lead to genomic instability, a characteristic finding in many human disorders. Therefore, integrity of DNA and fidelity of its repair mechanisms are important in AMD prevention and the potential of vitamin D to modulate DDR could also play a role in its properties (Fig. 3).

One of the earliest aspects of DDR is modulation of the cell cycle. 1,25(OH)2D has been shown to increase expression of the p18, p21 and p27 proteins in the head and neck cancer cell line (Gedlicka et al., 2006; Hager et al., 2001; Hager et al., 2004). These proteins are crucial for regulation of the cell cycle and it was observed that the vitamin D induced cell growth inhibition was due to the induction of G0/G1 arrest and this could be associated with an increased expression of p21 (Gedlicka et al., 2006). This increase could be linked with an elevated expression of p53, which is a master regulator of the cell cycle (Maguire & Campbell, 2010) [19]. Another
study demonstrated that 1,25(OH)2D induced arrest at the G1/S checkpoint in the response to mitogens (Shen & Ji, 2015). Therefore, regulation of the cell cycle can be an important mechanism of DDR modulation by vitamin D. However, it should be taken into account that in normal adult retina, the cells do not undergo cycling, i.e. they do not replicate. Retinal neurons are post-mitotic cells and RPE cells are G0 quiescent cells. However, when the RPE cells in the central retina are damaged, they can be replaced by their proliferating counterparts from the periphery (Al-Hussaini et al., 2008). Therefore, DDR with cell cycle regulation is essential for the proper functioning of RPE and the replacement of degraded cells, and failures in these processes have been directly associated with a slow progression of AMD to its final stage.

AMD has been associated with a permanent oxidative stress and ROS overproduction in retinal cells. Oxidative modifications of the DNA bases are the main DNA lesions induced by moderate levels of oxidative stress and 8-oxo-2'-deoxyguanosine (8oxoG) is a marker of DNA oxidation. In general, influence of vitamin D on the level of ROS-induced DNA damage, which is usually evaluated by the level of 8oxoG, suggests that it possesses a protective effect, but the mechanism underlying this action seems to be dependent on many factors, including the kind of cell/tissue and the underlying cellular conditions, as well as the VDR state (Fedirko et al., 2001). Therefore, vitamin D has the potential to substantially modulate the DDR, and this property can be included into the repertoire of possible ways in which this vitamin can prevent the occurrence and development of AMD. It should be emphasized that impairment of autophagy, which has been linked with AMD, can be considered as a DDR reaction.

**Autophagy**

Autophagy is a mechanism of cellular internal quality control, i.e. damaged or no longer needed cellular components, including organelles, are degraded in vesicles formed by the fusion of autophagy-specific autophagosomes with lysosomes (Mizushima, 2007). Autophagic degradation can also act against invaders, including viruses and bacteria. Autophagy can occur in three distinct forms: microautophagy, macroautophagy, which here will be subsequently simply called autophagy, and chaperone-mediated autophagy; many proteins are known to be important in its regulation, including about 30 autophagy-related proteins (ATGs), e.g. Beclin-1, mechanistic target of rapamycin (mTOR), the serine/threonine kinase 1 (ULK1), FIP-200, p62 (SQSTM1), microtubule-associated protein light chain 3 (LC3) and others (Blaszkiewicz et al., 2014).

Impaired autophagy impacts on the functioning of the RPE cells and is recognized as being crucial in the pathogenesis of many human diseases, including AMD (Chang et al., 2015; Li et al., 2015; Mitter et al., 2012). Its precise role in AMD is not fully understood, but dysfunctional autophagy leads to an increased accumulation of protein aggregates in the RPE cells, resulting from damage to cellular proteins by AMD risk factors (reviewed in: Blaszkiewicz et al., 2019). This is supported by the involvement of autophagy in the degradation of used photoreceptor outer segments by the RPE cells (Yu et al., 2018). The photoreceptor segment can be also removed by heterophagy and this process takes place on the apical side of RPE cells, associated with photoreceptor layer (Bosch et al., 1993). This supports the key role of RPE cells in AMD pathogenesis. Another mechanism is thought to involve accumulation of lipofuscin, yellow-brown pigment granules, in aging RPE cells, which are cleared in the lysosome (Kaarniranta et al., 2013). Impaired autophagy reduces efficiency of this process and can contribute to accelerated aging as well as potentiating other risk factors, including oxidative stress, which creates a vicious cycle-like state.

Vitamin D and its analogs can induce autophagy in normal and cancer cells via several mechanisms (Wu & Sun, 2011). Hoyer-Hansen and others (Hoyer-Hansen et al., 2007) demonstrated that autophagy could be induced by an increase in the cytosolic calcium concentration. They also showed that 1,25(OH)2D, as well as its chemotherapeutic analog EB 1089, induced an increase in the calcium level and autophagy in the breast cancer MCF-7 cells. Vitamin D analogs inhibited mTOR activity and induced accumulation of autophagosomes in a process dependent on Beclin-1 and ATG7. Other mediators of this process were Ca2+/calmodulin-dependent kinase kinase-β and AMP-activated protein kinase. Furthermore, the effects of these vitamin D analogs were inhibited by Bel-2 targeting endoplasmic reticulum.

However, the literature contains conflicting results, suggesting a dual role of calcium ions in autophagy as they can both, stimulate and inhibit this process (Decuyper et al., 2011).

Autophagy is considered as the bridge between the innate and adaptive immunity and vitamin D plays a key role in the immunological response (Shibutani et al., 2015). Consequently, an interrelationship linking this vitamin with autophagy could be observed in a pathogen infection, as such infection can potentially evoke both, the vitamin-D mediated immune response and the triggering of autophagy. For example, human cathelicidin hCAP-18/LL-37, an antimicrobial peptide, was claimed to be a link between vitamin D-dependent immunity and the pathways activated in autophagy (Jee et al., 2016; Yuk & Jo, 2013).

As mentioned above, vitamin D and its receptor signaling play an important role in inflammatory responses (Mangin et al., 2014). As there seems to be a clear connection between inflammation and autophagy, it can be assumed that vitamin D plays a role in the regulation of inflammation through autophagic mechanisms as is the case in inflammatory bowel disease (Suh et al., 2017). The anti-inflammatory autophagy-mediated actions of vitamin D may involve several mechanisms, including inhibition of TNF-α with a concomitant decrease in the Beclin-1 level, recruitment of ATG16, inhibition of IFN-γ.

It has been shown that vitamin D can trigger autophagic death in human myeloid leukemia cells by stimulating binding of Beclin-1 to class III phosphatidylinositol 3-kinase to induce autophagy (Wang et al., 2008). Vitamin D stimulated phosphorylation of the BH3 domain in the pro-apoptotic Bad (Bel-2-associated death promoter) protein, resulting in disassociation of the Bad/Bel-xL (B-cell lymphoma-extra large) complex with subsequent inhibition of apoptotic signals. Beclin-1 seems to be critical for these effects, as its knockdown abolished the proautophagic effect of vitamin D.

All of these mechanisms suggest that vitamin D and autophagy can be associated with innate immunity, inflammation, infection and cancer (Wu & Sun, 2011).
Unfortunately, there is a lack of information relating to vitamin D and autophagy in the retina – the only published study was conducted in the zebrafish eye/retina which was being used as a model of polyglutamine-related neurodegenerative disorders (Underwood et al., 2010). However, autophagy is a ubiquitous process, i.e. it is not strictly limited to some specific cells or tissues and therefore its modulation by vitamin D in the eye/retina is possible. Some of the putative relationships between vitamin D and autophagy which have originated from work done in cancer cells need to be interpreted with caution before extrapolating those findings to normal cells, since usually the experiments conducted with cancer cells have required high, non-physiological concentrations of this vitamin in order to obtain an antineoplastic effect. Currently, only a putative mechanism of involvement of autophagy in AMD pathogenesis can be considered (Fig. 4).

CONCLUSIONS AND PERSPECTIVES

It is not easy to answer the question posed in the title of this review, as some results on the protective potential of vitamin D in AMD are inconsistent or even contradictory. The most convincing evidence supporting the hypothesis that this vitamin exerts a beneficial effect in AMD originates from its abilities to modulate the immune system, as well as its ability to inhibit inflammation and angiogenesis.

There is no consensus about the precise concentration of vitamin D in the serum, for example, which levels should be considered as “normal” and “lower/higher than normal”. However, some kind of consensus seems to be reached and some guidelines can be followed (reviewed in: Pludowski et al., 2013; Pludowski et al., 2018). Still, these guidelines focus mainly on particular aspects on vitamin D metabolism. When the role of this vitamin in bone is considered, the optimal recommended level of 25(OH)D in the serum is 20 ng/mL with daily doses of 400-800 IU, depending on age. When pleiotropic effects of vitamin D are considered, a concentration of 30 ng/mL 25(OH)D and daily doses 400-2000 IU are recommended, depending on age, BMI, health status and ethnicity.

According to various sources, including the Vitamin D Council, the Endocrine Society and the Institute of Medicine, the same concentration of 25(OH)D in the serum can be considered as either a sufficient or a deficient level of the vitamin (Mangin et al., 2014). Therefore, the cut-off value for sufficiency and deficiency of 25(OH)D in the serum should be validated by results from experimental and epidemiological research. This is a serious problem, as these results should be adjusted to an “average individual” level. Autophagy, as a mechanism of cellular action of vitamin D in AMD, seems especially important in the context of this vitamin’s preventive potential against AMD, as impaired autophagy has been associated with several critical features of AMD pathogenesis. Impaired autophagy has been implicated in other aspects of AMD pathophysiology, including an impaired DDR and activation of the inflammasome, as autophagy can be involved in both processes (Hyttinen et al., 2017). As vitamin D can play a role in regulation of inflammation through autophagic mechanisms, as shown for the inflammatory bowel disease, it may be also able to influence AMD through an identical or a similar mechanism. Autophagy can lead to protection of AMD-affected retinal cells from cell death, but it could also accelerate their demise, and switching between these two effects could be dependent on many factors. Therefore, interconnections between AMD, autophagy and inflammation in the context of the regulatory role of vitamin D in inflammation need to be addressed in further research.

Degeneration of the retina is another important issue to be considered in assessing the potential of vitamin D to modulate AMD. It has been suggested that cellular senescence is a key process contributing to degeneration of retina cells encountered in AMD (Kozlowski, 2015), and we have developed this hypothesis (Blasiak et al., 2017). In the normal adult human eye, the RPE cells of the central retina are quiescent and not able to proliferate due to spatial restrictions. If they are occasionally damaged, they can be replaced by their proliferating counterparts from the periphery (Al-Hussaini et al., 2008). However, if the majority of RPE cells are senescent, the compensating mechanisms can fail and lead to AMD progression. Oxidative stress has been shown to induce senescence in the RPE cells, but the exact mechanism has not been clarified (Aryan et al., 2016). The release of pro-inflammatory cytokines and ROS by senescent cells, DNA damage-induced senescence, induction of senescence in neighboring cells, as well as the interplay between senescence and autophagy are considered to regulate RPE degeneration (Sikora et al., 2014). There-
fore, it would be interesting to examine whether vitamin D can modulate senescence in RPE cells or more extensively in other retinal cells.

In conclusion, there are many pathways through which vitamin D can affect AMD, mainly by modulating effects associated with the disease. Vitamin D has the potential to both, prevent and slow down the progress of AMD, but several issues, including the dose-dependency of this vitamin, its influence on diseases coexisting with AMD, the individual’s exposure to sunlight as a factor influencing the activation of this vitamin as well as other risk factors in AMD, need to be addressed before drawing any definite conclusions about the protective role of vitamin D in AMD. It is essential that there should be a resolution of these unanswered questions before it will be possible to issue any dietary recommendations about the dose of vitamin D to be taken by AMD patients.

Acknowledgments

We thank Ewen MacDonald for language editing and Monika Kicinska for her help in figures’ preparation.

Conflicts of Interest

The authors declare no conflict of interest.

REFERENCES

Ahn J, Park S, Zuniga B, Bera A, Song CS, Chatterjee B (2016) Vitamin D and cellular senescence in age-related macular degeneration. *Vitam Horm* 100: 321–355. https://doi.org/10.1016/B978-0-12-809624-0.00043-7

Bosch E, Horwitz J, Bok D (1993) Phagocytosis of outer segments by retinal pigment epithelial cells: Evidence for a vitamin D receptor-regulated function. *J Histochem Cytochem* 41: 253–263. https://doi.org/10.1177/144062899304100210

Broadhead GK, Grigg JR, Chang AA, Mccluskey P (2015) Dietary modulation and supplementation for the treatment of age-related macular degeneration. *Nutr Rev* 73: 448–462. https://doi.org/10.1093/nutrrev/nvu005

Chang YC, Hsieh MC, Wu HJ, Wu WC, Kao YH (2015) Methyglyoxal, a reactive glucose metabolite, enhances autophagy flux and suppresses proliferation of human retinal pigment epithelial arpe-19 cells. *Toxins* 7: 1358–1368. https://doi.org/10.3390/toxins7121358

Chatterjee M (2001) Vitamin D and genomic stability. *Mutat Res* 475: 69–87.

Chew EY (2017) Nutrition, genes, and age-related macular degeneration: What have we learned from the trials? *Opticalinguia* 238: 1–5.

Chew EY, Clemons TE, SanGiovanni JP, Davis MD, Ferris FL (2012) The age-related eye disease study 2 (AREDS2): Study design and baseline characteristics (AREDS2 report number 1). *Optimol Sci* 119: 2282–2289. https://doi.org/10.1007/s11159-012-9856-6

Chohbemrilo S, Bjorlkund G, Shoaarina A, Vella A (2017) The role of vitamin D in the immune system as a pro-survival molecule. *Clin Liver* 39: 894–916. https://doi.org/10.1007/s11378-017-0502-1

Cristakos S, Dhawan P, Porta A, Mady LJ, Seth T (2011) Vitamin D and facial aging: Is there a link? *Skin Pharmacol Physiol* 24: 13378-13397. https://doi.org/10.1159/000443839

Day S, Acquah K, Platt A, Lee PP, Mruthyunjaya P, Sloan FA (2012) The role of vitamin D in the immune system as a pro-survival molecule. *Mol Cell Endocrinol* 347: 25–29. https://doi.org/10.1016/j.mce.2017.06.005

Duffy NM, Balkey OA, Shoeb MA, Ismael RN (2016) Serum vitamin D and facial aging: Is there a link? *Skin Pharmacol Physiol* 29: 76–82. https://doi.org/10.1159/000468385

Ebeling PR, Sandgren ME, DiMagno EP, Lane AW, DeLuca HF, Egan SJ, Greenberg NM, Christakos S, Dhawan P, Porta A, Mady LJ, Seth T (2011) Vitamin D and facial aging: Is there a link? *Skin Pharmacol Physiol* 24: 13378-13397. https://doi.org/10.1159/000443839

Everett AV, Hlamer SN, Brand-Miller JC, Jamieson HA, Trustwell AS, Sharma AP, Mason RS, Morris BJ, Le Couteur DG (2006) Dietary approaches that delay age-related diseases. *Clin Interv Aging* 1: 11-31.

Ebeling PR, Sandgren ME, DiMagno EP, Lane AW, DeLuca HF, Rigs RG (1992) Evidence of an age-related decrease in intestinal responsiveness to vitamin D. *J Clin Endocrinol Metab* 75: 99–106. https://doi.org/10.1210/jcem.75.1.3301488

Forschungskoala C, Halauha D, Kundi M (2017) 25-hydroxyvitamin d status and risk for colorectal cancer and type 2 diabetes mellitus: A systematic review and meta-analysis of epidemiological studies. *Int J Environ Res Public Health* 14(12): 1610. https://doi.org/10.3390/ijerph14121610

Gupta R, Arora AD, Stein RJ, Longmire A, Shayan J, De royalty E, Shroff R, Choudhury M, Das SK, Belli D, Ostu T, Wang J (2017) Vitamin D: Benefits and therapeutic potential. *Nutrients* 9(7): 768026. https://doi.org/10.3390/nu9070768026
Hill TR, Aspray TJ (2017) The role of vitamin d in maintaining bone health in older people. Ther Adv Musculoskelet Dis 9: 89–95. https://doi.org/10.1177/1759720617692502

Hill TR, Aspray TJ, Francis RM (2013) Vitamin d and bone health outcomes in older age. Ageing Res Rev 12: 372–380. https://doi.org/10.1016/j.arr.2012.03.006

Hisa T, Taniguchi S, Tsuruta D, Hirachi Y, Ishizuka S, Takigawa M (1996) Vitamin d inhibits endothelial cell migration. Arteriothromb 16: 282–262.

Hjelmeland LM (2011) Dark matters in amd genetics: Epigenetics and stochasticity. Invest Ophthalmol Vis Sci 52: 1622–1631. https://doi.org/10.1167/iovs.09-4765

Horst RJ, Geoff JS, Rembacka TA (1990) Advancing age results in reduction of intestinal and bone 1,25-dihydroxyvitamin d3 receptor. Endocrinology 126: 1053–1057. https://doi.org/10.1210/endo-126-2-1053

Hoyer-Hansen M, Bastholm L, Sznajderiowski P, Campanella M, Szabadkai G, Farkas T, Bianchi F, Fehrenbacher N, Elling F, Rizzuto R, Mathiasen IS, Jaatta M (2007) Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and bel-2. Mol Cell 25: 193–205. https://doi.org/10.1016/j.molcel.2006.12.009

Hutchinson JN, Fagemers J, Kirby A, Reynolds R, Zazk A, Gimeñelbrant A, Plenge R, Daly M, Chess A, Seddon JM (2014) epigenetic analyses of age-related macular degeneration: Case control and discordant twin studies. Hum Hered 78: 59–72. https://doi.org/10.1159/000362814

Hyttinen JM, Blasjak J, Niittymäki S, Kinnunen K, Kauppinen A, Salminen A, Kaarniranta K (2017) DNA damage response and autophagy in the degeneration of retinal pigment epithelial cells: implications for age-related macular degeneration (amd). Aging Res Rev 36: 64–77. https://doi.org/10.1016/j.arr.2017.03.006

Itray D, Sylves KW, Jones HC, Pecaut LM, Mruthyunjaya P (2014) Vitamin d deficiency in neovascular versus nonneovascular age-related macular degeneration. Retina 34: 1779–1786. https://doi.org/10.1097/IAE.000000000000178

Jaretz SG, Boulton ME (2012) Consequences of oxidative stress in age-related macular degeneration. Mol Aspects Med 33: 395–417. https://doi.org/10.1016/j.mam.2013.02.009

Jee D, Kang S, Yuan C, Cho E, Arroyo JG (2016) Serum 25-hydroxyvitamin d levels and dry eye syndrome: Differential effects of vitamin d on ocular diseases. PLoS One 11: e0149294. https://doi.org/10.1371/journal.pone.0149294

Kaarminna K, Sinha D, Blasjak I, Kauppinen A, Vereh Z, Salminen A, Boulton ME, Petrovski G (2013) Autophagy and heterophagy dysregulation leads to retinal pigment epithelium dysfunction and development of age-related macular degeneration. Autophagy 9: 973–984. https://doi.org/10.4161/auto.24546

Kaarniranta K, Tokarz P, Koskelo A, Pateron J, Blasjak I (2017) Age-related macular degeneration. Mol Aspects Med 33: 395–417. https://doi.org/10.1016/j.mam.2013.02.009

Kallus E, Barcis P, Bajna E, Lencz T, Simon S, Bonner E, Toyokuni S, Cross KR (2002) Vitamin d receptor activity and prevention of colonic hyperproliferation and oxidative stress. Food Chem Toxicol 40: 1191–1196

Kanaki T, Makrantoniaki E, Zouboulis CC (2016) Biomarkers of skin aging. Rev Endocr Metab Disord 17: 433–442. https://doi.org/10.1007/s11590-016-9371-8

Kalus E, Barcis P, Bajna E, Lencz T, Simon S, Bonner E, Toyokuni S, Cross KR (2002) Vitamin d receptor activity and prevention of colonic hyperproliferation and oxidative stress. Food Chem Toxicol 40: 1191–1196

Kanaki T, Makrantoniaki E, Zouboulis CC (2016) Biomarkers of skin aging. Rev Endocr Metab Disord 17: 433–442. https://doi.org/10.1007/s11590-016-9371-8

Kato M (2013) Therapeutics targeting angiogenesis: Genetics and epi-genetics, extracellular matrix, and signaling networks (review). Int J Mol Med 32: 763–767. https://doi.org/10.3892/ijmm.2013.1444

Kauppinen A, Paterson J, Blasjak I, Salminen A, Kaarniranta K (2016) Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci 73: 1763–1786. https://doi.org/10.1007/s00018-016-2147-8

Kernacki KA, Berk RS (1994) Characterization of the inflammatory response induced by corneal injury with pseudomonal aeruginosa. Ophthalm Plast Reconstr Surg 10: 281–286

Kieh EC, Han K, Jee D (2014) Inverse relationship between high blood 25-hydroxyvitamin d and late stage of age-related macular degeneration in a representative korean population. Invest Ophthalmol Vis Sci 55: 4823–4831. https://doi.org/10.1167/iovs.13-14763

Kim HJ, Ji M, Song J, Moon HW, Hur M, Yun YM (2017) Clinical expression of the cell cycle inhibitor p18 in a squamous cell carcinoma cell line of the head and neck. J Oral Pathol Med 35: 472–478. https://doi.org/10.1111/j.1600-0040.2004.00407.x

Kim EC, Han K, Jee D (2014) Inverse relationship between high blood 25-hydroxyvitamin d levels and dry eye syndrome: Differential effects of vitamin d on ocular diseases. PLoS One 11: e0149294. https://doi.org/10.1371/journal.pone.0149294

Kim HJ, Ji M, Song J, Moon HW, Hur M, Yun YM (2017) Clinical utility of measurement of vitamin d-binding protein and calculation of bioavailable vitamin d in assessment of vitamin d status. Ann N Y Acad Sci 1367–1369. https://doi.org/10.1177/1759720X17692502

Kinyamu HK, Gallagher JC, Petranick KM, Ryschon KL (1996) Effect of bioavailable vitamin d in assessment of vitamin d status. J Nutr 126: 1535–1541. https://doi.org/10.1093/jn/126.5.1535

Kozlowski MR (2015) The arpe-19 cell line: Mortality status and utilization in macular degeneration research. Trends Biochem Sci 40: 57–69. https://doi.org/10.1016/j.tibs.2015.09.002

Kwa FA, Thrimawithana TR (2014) Epigenetic modifications as potential therapeutic targets in age-related macular degeneration and
diabetic retinopathy. *Drug Discov Today* 19: 1387–1393. https://doi.org/10.1016/j.drudis.2013.04.036

Lee V, Rehli E, Hoh Kam J, Jeffery G (2012) Vitamin d rejuvenates aging eyes by reducing inflammation, clearing amyloid beta and improving visual function. *Neurobiol Aging* 33: 2382–2389. https://doi.org/10.1016/j.neurobiolaging.2011.12.002

Li YJ, Jiang Q, Cao GF, Yao J, Yan B (2015) Repertoires of autophagy in the pathogenesis of ocular diseases. *Cell Physiol Biochem* 35: 1663–1671. https://doi.org/10.1155/2015/697017

Liao SM, Zheng W, Zhu J, Lewis CA, Delgado O, Crowley MA, Buchanan NM, Jaffe BD, Dryja TP (2017) Specific correlate between the major chromosome 10q26 haplotype conferring risk for age-related macular degeneration and the expression of htra1. *Mol Vis* 23: 318–333

Liu MM, Chan CC, Tuo J (2012) Genetic mechanisms and age-related macular degeneration: Common variants, rare variants, copy number variations, and epigenetics, and mitochondria. *Genome 6* 13. https://doi.org/10.1016/j.1479-7364.6.13

Lyzogubov VV, Bora PS, Wu X, Horn LE, de Roque R, Rudolf XV, Akkinson JP, Bora NS (2016) The complement regulatory protein CD46 deficient mouse spontaneously develops dry-type age-related macular degeneration-like phenotype. An Ophthalmol. https://doi.org/10.1016/j.libao.2016.03.021

MacLaughlin J, Holick MF (1985) Aging decreases the capacity of human skin to produce vitamin d3. *J Clin Invest* 76: 1536–1538. https://doi.org/10.1172/jci112134

Maguire O, Campbell MJ (2010) Vitamin d and p53-differentiating melanoma. *Cancer Biol Ther* 10: 351–353

Mangin M, Sinha R, Fincher K (2014) Inflammation and vitamin d: Lipid metabolism in the pathogenesis of age-related macular degeneration in postmenopausal women. *Am J Pathol* 184: 372. https://doi.org/10.1016/j.ajpath.2013.05.016

Mariotti C, Casuccio A (2016) Geo-epidemiology of age-related macular degeneration-like phenotype. *Invest Ophthalmol Vis Sci* 57: 318–333

Mebius RE, Roux O, Sabatini D, Zoller S, Seiler CM, Kettler J, Kretzschmar H, Voigt WD, Wellmann F, Schwickert J, Scholkens B, Klein BEK, La-Monte MJ, Fritsche LA (2017) Association between vitamin d status and age-related macular degeneration in the European eye study. *Ophthalmologica* 234: 238–249. https://doi.org/10.1159/000487672

Methven EH, Smulian JC, D’Souza JA, Bird AC, Dhillon S, Patil K, Hamblin MR, Wormald R, Sefton I, Goecke SJ, Lawrence MK, Meade TW, Johnson AL, Appleton D, Stavrakis S, Hales S, Pain A, Jones G, Humphries SE, Simonson DC, Christensen K, Goodship TJ, Reade PC, O’Connor S, Balfe I, Andrews CA, Klein R (2013) Vitamin d and advanced age-related macular degeneration: An institutional experience and review. *Am J Ophthalmol* 155: 21–28. https://doi.org/10.1016/j.ajo.2012.08.039
Sikora E, Bielak-Zmijewska A, Mosieniak G (2014) Cellular senescence in ageing, age-related disease and longevity. *Curr Vasc Pharmacol* 12: 698–706

Singh A (2014) Systemic changes in neovascular age-related macular degeneration. *Dan Med J* 61: B4872

Stevens R, Bartlett H, Cooke R (2015) Dietary analysis and nutritional behaviour in people with and without age-related macular disease. *Clin Nutr ESPEN* 10: e112–e117. https://doi.org/10.1016/j.clnesp.2015.03.080

Sah HW, Kim JK, Kim YS, Jo EK (2017) New insights into vitamin d and autophagy in inflammatory bowel diseases. *Curr Med Chem* 24: 711–720. https://doi.org/10.2174/0929867324666161202151856

Suzuki T, Sano Y, Kinoshita S (2000) Effects of 1alpha,25-dihydroxyvitamin d3 on langerhans cell migration and corneal neovascularization in mice. *Invest Ophthalmol Vis Sci* 41: 154–158

Suzuki T, Sano Y, Sotozono C, Kinoshita S (2000) Regulatory effects of 1alpha,25-dihydroxyvitamin d3 on cytokine production by human corneal epithelial cells. *Curr Eye Res* 20: 127–130

Synowiec E, Blasik J, Zaras M, Szaflik J, Szaflik JP (2012) Association between polymorphisms of the DNA base excision repair genes mutyh and hogg1 and age-related macular degeneration. *Exp Eye Res* 98: 58–66. https://doi.org/10.1016/j.exer.2012.02.008

Szaflik JP, Janik-Paplik K, Synowiec E, Ksiazek D, Zaras M, Wozniak K, Szaflik J, Blasik J (2009) DNA damage and repair in age-related macular degeneration. *Mutat Res* 669: 169–176. https://doi.org/10.1016/j.mrfmmm.2009.06.008

Tulk SE, Liao KC, Muruve DA, Li Y, Beck PI, MacDonald JA (2015) Vitamin d(3) metabolites enhance the nlrp3-dependent secretion of il-1beta from human thp-1 monocytic cells. *J Cell Biochem* 116: 711–720. https://doi.org/10.1002/jcb.24985

Underwood BR, Imarisio S, Fleming A, Rose C, Krishna G, Heard P, Quick M, Korolechuk VI, Renza M, Sarkar S, Garcia-Arencibia M, O’Kane CJ, Murphy MP, Rubinsztein DC (2010) Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease. *Hum Mol Genet* 19: 3413–3429. https://doi.org/10.1093/hmg/ddq283

Uto M, Beauchet O, Cherif M, Graffe A, Miles D, Annweiler C (2015) Age-related vitamin d deficiency is associated with reduced macular ganglion cell complex: A cross-sectional high-definition optical coherence tomography study. *PLoS One* 10: e0130879. https://doi.org/10.1371/journal.pone.0130879

Wang J, Lian H, Zhao Y, Kauss MA, Spindel S (2008) Vitamin d3 induces autophagy of human myeloid leukemia cells. *J Biol Chem* 283: 25536–25545. https://doi.org/10.1074/jbc.M801716200

Wang JJ, Roehnshena F, Lee AJ, Chia EM, Smith W, Cumming RG, Mitchell P (2007) Ten-year incidence and progression of age-related maculopathy: The blue mountains eye study. *Ophthalmology* 114: 92–98. https://doi.org/10.1016/j.ophtha.2006.07.017

Wong G, Gupta R, Dixon KM, Deco SS, Choong SM, Halliday GM, Bishop JE, Ishizuka S, Norman AW, Posner GH, Mason RS (2004) 1,25-dihydroxyvitamin d and three low-calcemic analogs decrease uv-induced DNA damage via the rapid response pathway. *J Steroid Biochem Mol Biol* 89–90: 567–570. https://doi.org/10.1016/j.jsbmb.2004.03.072

Wu S, Sun J (2011) Vitamin d, vitamin d receptor, and macroautophagy in inflammation and infection. *Diabetes Metab* 37: 325–335.

Xiong Y, Liu Y, Su H, Fu Y, Kong J (2016) 1,25-dihydroxyvitamin d and three low-calcemic analogs decrease uv-induced DNA damage via the rapid response pathway. *Exp Eye Res* 100: 386–392. https://doi.org/10.1016/j.exer.2016.03.003

Xu G, Wang J, Gao GF, Liu CH (2014) Insights into battles between mycobacterium tuberculosis and macrophages. *Protein Cell* 5: 728–736. https://doi.org/10.1007/s13238-014-0077-5

Yu B, Egbejimi A, Dharmat R, Xu P, Zhao Z, Long B, Miao H, Chen R, Wensel TG, Cai J, Chen Y (2018) Phagocytosed photoreceptor outer segments activates mtorc1 in the retinal pigment epithelium. *Sci Signal* 11: https://doi.org/10.1126/scisignal.aas3315

Zhou BB, Elledge SJ (2000) The DNA damage response: Putting checkpoints in perspective. *Nature* 408: 433–439. https://doi.org/10.1038/35044005